Govindasamy Manikam

Title: Innovator in Diabetes Treatment: Govindasamy Manikam

Introduction

Govindasamy Manikam is a notable inventor based in Bengaluru, India. He has made significant contributions to the field of diabetes treatment through his innovative research and development work. His dedication and expertise have led to the formulation of a patent that aims to improve insulin delivery methods.

Latest Patents

Govindasamy holds a patent for the "Process for the preparation of insulin conjugate IN-105." This invention claims a process for creating an insulin-oligomer conjugate known as IN-105. The patent details the cloning and expression of the IN-105 precursor, which has a specific formula: G-A-V-R-[B-Chain]-R-D-A-D-D-R-[A-Chain]. The biosynthetic precursor is intricately conjugated with an activated oligomer. Following this, the IN-105 precursor-oligomer conjugate undergoes treatment with protease and is purified to yield an active insulin-oligomer conjugate represented by the formula insulin-OC—CH—CH—(OCHCH)—OCH.

Career Highlights

Govindasamy is currently employed at Biocon Limited, a leading biopharmaceutical company known for its innovative approaches to healthcare. His role in the company highlights his commitment to advancing medical technology, particularly in the area of diabetes management.

Collaborations

Throughout his career, Govindasamy has collaborated with notable colleagues such as Nitesh Dave and Partha Hazra. These professionals contribute to a dynamic environment that fosters creativity and innovation within Biocon Limited, making substantial strides in therapeutic solutions.

Conclusion

Govindasamy Manikam stands out as a key innovator in the field of diabetes treatment through his pioneering work in insulin conjugates. His patent for IN-105 showcases his commitment to developing advanced therapies that can make a real difference in patients' lives. With continued collaboration and innovation, Govindasamy is poised to contribute further to the medical community and diabetes care.